(Q33357735)

English

Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Lars Möllgård

5

object named as

Lars Möllgård

0 references

author name string

Gunnar Juliusson

1

1 reference

Europe PubMed Central

26 July 2017

Martin Höglund

2

1 reference

Europe PubMed Central

26 July 2017

Karin Karlsson

3

1 reference

Europe PubMed Central

26 July 2017

Christina Löfgren

4

1 reference

Europe PubMed Central

26 July 2017

Lars Möllgård

5

1 reference

Europe PubMed Central

26 July 2017

Christer Paul

6

1 reference

Europe PubMed Central

26 July 2017

Ulf Tidefelt

7

1 reference

Europe PubMed Central

26 July 2017

Magnus Björkholm

8

1 reference

Europe PubMed Central

26 July 2017

Leukemia Group of Middle Sweden

9

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

1 December 2003

1 reference

Europe PubMed Central

26 July 2017

British Journal of Haematology

1 reference

Europe PubMed Central

26 July 2017

123

1 reference

Europe PubMed Central

26 July 2017

5

1 reference

Europe PubMed Central

26 July 2017

810-818

1 reference

Europe PubMed Central

26 July 2017

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

In AML Cell Lines Ara-C Combined with Purine Analogues is Able to Exert Synergistic as Well as Antagonistic Effects on Proliferation, Apoptosis and Disruption of Mitochondrial Membrane Potential

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK)

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04702.X

21 January 2018

Identifiers

10.1046/J.1365-2141.2003.04702.X

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33357735&oldid=2049931267"